Literature DB >> 24638861

The role of the inflammasome in cardiovascular diseases.

Xuan Li1, Nicolas Deroide, Ziad Mallat.   

Abstract

Inflammasome is a very important signaling platform sensing a variety of triggers of the innate immune system. Inflammasome promotes the production of important pro-inflammatory cytokines such as IL-1β and IL-18. Tight control of inflammasome activity is, therefore, essential and occurs at multiple levels. The activation of inflammasome pathways is linked to the pathogenesis of various prevalent disorders including cardiovascular disease such as atherosclerosis, ischemic injury, cardiomyopathy, and Kawasaki disease. The study of the inflammasome in the cardiovascular system has led to the identification of important triggers and endogenous modulators, and to the exploration of new treatment strategies based on the inhibition of inflammasome activation or its end products, i.e., IL-1β and IL-18. In summary, the discovery of the inflammasome has greatly advanced our understanding of how the innate immune system interferes with cardiovascular disease development and progression, and targeting inflammasome provides new avenues for the treatment and management of cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24638861     DOI: 10.1007/s00109-014-1144-3

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  155 in total

1.  Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1.

Authors:  Olaf Gross; Amir S Yazdi; Christina J Thomas; Mark Masin; Leonhard X Heinz; Greta Guarda; Manfredo Quadroni; Stefan K Drexler; Jurg Tschopp
Journal:  Immunity       Date:  2012-03-23       Impact factor: 31.745

Review 2.  Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu.

Authors:  K Nakanishi; T Yoshimoto; H Tsutsui; H Okamura
Journal:  Cytokine Growth Factor Rev       Date:  2001-03       Impact factor: 7.638

Review 3.  Inflammasomes in carcinogenesis and anticancer immune responses.

Authors:  Laurence Zitvogel; Oliver Kepp; Lorenzo Galluzzi; Guido Kroemer
Journal:  Nat Immunol       Date:  2012-03-18       Impact factor: 25.606

4.  Haplotypes of the caspase-1 gene, plasma caspase-1 levels, and cardiovascular risk.

Authors:  Stefan Blankenberg; Tiphaine Godefroy; Odette Poirier; Hans J Rupprecht; Sandrine Barbaux; Christoph Bickel; Viviane Nicaud; Renate Schnabel; Frank Kee; Caroline Morrison; Alun Evans; Karl J Lackner; François Cambien; Thomas Münzel; Laurence Tiret
Journal:  Circ Res       Date:  2006-06-15       Impact factor: 17.367

5.  Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta.

Authors:  B J Pomerantz; L L Reznikov; A H Harken; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

6.  Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia.

Authors:  Faisal M Syed; Harvey S Hahn; Amy Odley; Yiru Guo; Jesus G Vallejo; Roy A Lynch; Douglas L Mann; Roberto Bolli; Gerald W Dorn
Journal:  Circ Res       Date:  2005-04-21       Impact factor: 17.367

7.  Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine.

Authors:  Edward C Keystone; Millie M Wang; Mark Layton; Sally Hollis; Iain B McInnes
Journal:  Ann Rheum Dis       Date:  2012-10       Impact factor: 19.103

8.  Genetic and pharmacologic disruption of interleukin-1β signaling inhibits experimental aortic aneurysm formation.

Authors:  William F Johnston; Morgan Salmon; Gang Su; Guanyi Lu; Matthew L Stone; Yunge Zhao; Gary K Owens; Gilbert R Upchurch; Gorav Ailawadi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-01-03       Impact factor: 8.311

9.  Inflammasomes are differentially expressed in cardiovascular and other tissues.

Authors:  Y Yin; Y Yan; X Jiang; J Mai; N C Chen; H Wang; X-F Yang
Journal:  Int J Immunopathol Pharmacol       Date:  2009 Apr-Jun       Impact factor: 3.219

10.  Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1α and sterile vascular inflammation in atherosclerosis.

Authors:  Stefan Freigang; Franziska Ampenberger; Adrienne Weiss; Thirumala-Devi Kanneganti; Yoichiro Iwakura; Martin Hersberger; Manfred Kopf
Journal:  Nat Immunol       Date:  2013-09-01       Impact factor: 25.606

View more
  11 in total

1.  Endothelial-to-mesenchymal transition drives atherosclerosis progression.

Authors:  Pei-Yu Chen; Lingfeng Qin; Nicolas Baeyens; Guangxin Li; Titilayo Afolabi; Madhusudhan Budatha; George Tellides; Martin A Schwartz; Michael Simons
Journal:  J Clin Invest       Date:  2015-10-26       Impact factor: 14.808

Review 2.  Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector?

Authors:  Justine M Abais; Min Xia; Yang Zhang; Krishna M Boini; Pin-Lan Li
Journal:  Antioxid Redox Signal       Date:  2015-01-19       Impact factor: 8.401

3.  Mesenchymal stem cell transplantation inhibited high salt-induced activation of the NLRP3 inflammasome in the renal medulla in Dahl S rats.

Authors:  Qing Zhu; Xiao-Xue Li; Weili Wang; Junping Hu; Pin-Lan Li; Sabena Conley; Ningjun Li
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-13

Review 4.  NLRP3 Inflammasome Signaling as a Link Between HIV-1 Infection and Atherosclerotic Cardiovascular Disease.

Authors:  Caroline Mullis; Talia H Swartz
Journal:  Front Cardiovasc Med       Date:  2020-06-11

5.  Adipocyte-derived Lysophosphatidylcholine Activates Adipocyte and Adipose Tissue Macrophage Nod-Like Receptor Protein 3 Inflammasomes Mediating Homocysteine-Induced Insulin Resistance.

Authors:  Song-Yang Zhang; Yong-Qiang Dong; Pengcheng Wang; Xingzhong Zhang; Yu Yan; Lulu Sun; Bo Liu; Dafang Zhang; Heng Zhang; Huiying Liu; Wei Kong; Gang Hu; Yatrik M Shah; Frank J Gonzalez; Xian Wang; Changtao Jiang
Journal:  EBioMedicine       Date:  2018-04-27       Impact factor: 8.143

6.  Inflammasome activity in leucocytes decreases with abdominal aortic aneurysm progression.

Authors:  Philipp Erhart; Sinan Cakmak; Caspar Grond-Ginsbach; Maani Hakimi; Dittmar Böckler; Susanne Dihlmann
Journal:  Int J Mol Med       Date:  2019-08-07       Impact factor: 4.101

7.  Interleukin-18 in patients with acute coronary syndromes.

Authors:  Axel Åkerblom; Stefan K James; Tatevik G Lakic; Richard C Becker; Christopher P Cannon; Philippe G Steg; Anders Himmelmann; Hugo A Katus; Robert F Storey; Lars Wallentin; W Douglas Weaver; Agneta Siegbahn
Journal:  Clin Cardiol       Date:  2019-10-09       Impact factor: 2.882

8.  Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway.

Authors:  Yu Liu; Da-Wei Wang; Dan Wang; Bin-Hong Duan; Hong-Yu Kuang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-19       Impact factor: 5.555

9.  Epigenetic hypomethylation and upregulation of NLRC4 and NLRP12 in Kawasaki disease.

Authors:  Ying-Hsien Huang; Mao-Hung Lo; Xin-Yuan Cai; Ho-Chang Kuo
Journal:  Oncotarget       Date:  2018-04-10

10.  Deficiency in Aim2 affects viability and calcification of vascular smooth muscle cells from murine aortas and angiotensin-II induced aortic aneurysms.

Authors:  Markus Wortmann; Muhammad Arshad; Maani Hakimi; Dittmar Böckler; Susanne Dihlmann
Journal:  Mol Med       Date:  2020-09-15       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.